🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

181 results for “anti-” Clear

  1. Anti-CD30 CAR T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adult T-Cell Lymphoma/Leukaemia

    phase 1 gene therapy active

    1 trial

  2. Anti-CD5 CAR NK cells

    Chongqing Precision Biotech Co., Ltd

    T-ALL/Lymphoma

    phase 1 mab active

    1 trial

  3. Anti-CDH17 CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CDH17-positive Advanced Solid Tumors

    phase 1 mab active

    1 trial

  4. Anti-CLL1 CART cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  5. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  6. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  7. Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

    Takeda

    Systemic Lupus Erythematosus

    phase 1 small molecule terminated

    1 trial

  8. Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

    Takeda

    Metastatic Adenocarcinoma of the Colon or Rectum

    phase 1 mab completed

    1 trial

  9. Anti-SEMA4D Monoclonal Antibody VX15/2503

    VACCINEX, INC.

    Metastatic Melanoma

    phase 1 mab terminated

    1 trial

  10. Anti-SEMA4D Monoclonal Antibody VX15/2503

    VACCINEX, INC.

    Colon Carcinoma Metastatic in the Liver

    phase 1 mab completed

    1 trial

  11. Anti-human CCL24 monoclonal antibody (CM-101)

    Chemomab Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

  12. Anti-human CCL24 monoclonal antibody (CM-101) - Part One

    Chemomab Therapeutics

    Nonalcoholic Fatty Liver Disease

    phase 1 small molecule completed

    1 trial

  13. CHS-006 (anti-TIGIT)

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  14. Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma (DLBCL)

    phase 1 small molecule active

    1 trial

  15. First-in-human Study to Test Safety and Anti-tumor Activity of a Novel Drug for Patients with Advanced Solid Tumor Harboring Genetic Alterations in MET

    Turn Therapeutics

    Phase 1: Advanced solid tumors harboring genetic alterations in MET

    phase 1 other active

    1 trial

  16. Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumor

    phase 1 small molecule active

    1 trial

  17. Humanized anti-CD117 Monoclonal Antibody (JSP191)

    Jasper Therapeutics

    MYELODYSPLASTIC SYNDROME; MDS

    phase 1 mab active

    1 trial

  18. In situ injection of anti-angiogenics in patients with brain arteriovenous malformations not eligible for exclusion treatment: phase I trial (BLITZ)

    Pari Pharma GmbH

    Cardiology and vascular disease

    phase 1 other active

    1 trial

  19. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna Therapeutics

    Multiple Sclerosis

    phase 1 mab active

    1 trial

  20. Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  21. Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer

    Amgen

    Small Cell Lung Cancer

    phase 1 other active

    1 trial

  22. Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310)

    Amgen

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 1 other active

    1 trial

  23. Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo

    Shanghai University of Traditional Chinese Medicine

    Healthy

    phase 1 small molecule completed

    1 trial

  24. TL011, anti CD20, for the treatment of rheumatoid arthritis

    Teva Pharma GmbH

    Rheumatoid Arthritis

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources